CO2023017358A2 - Formulaciones de proteínas quiméricas del factor viii y usos de las mismas - Google Patents

Formulaciones de proteínas quiméricas del factor viii y usos de las mismas

Info

Publication number
CO2023017358A2
CO2023017358A2 CONC2023/0017358A CO2023017358A CO2023017358A2 CO 2023017358 A2 CO2023017358 A2 CO 2023017358A2 CO 2023017358 A CO2023017358 A CO 2023017358A CO 2023017358 A2 CO2023017358 A2 CO 2023017358A2
Authority
CO
Colombia
Prior art keywords
factor viii
formulations
chimeric factor
viii proteins
polypeptide
Prior art date
Application number
CONC2023/0017358A
Other languages
English (en)
Inventor
Tyler Carlage
Randall Mauldin
Loubna Mzaalak Tazi
Timothy R Mccoy
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of CO2023017358A2 publication Critical patent/CO2023017358A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona composiciones farmacéuticas de una proteína quimérica que comprende un polipéptido de factor VIII (FVIII) y un polipéptido de factor von Willebrand (VWF). También se divulgan kits farmacéuticos y métodos para utilizar las composiciones farmacéuticas divulgadas para tratar la hemofilia A.
CONC2023/0017358A 2021-06-23 2023-12-14 Formulaciones de proteínas quiméricas del factor viii y usos de las mismas CO2023017358A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163214245P 2021-06-23 2021-06-23
US202163214246P 2021-06-23 2021-06-23
US202163214752P 2021-06-24 2021-06-24
US202163231909P 2021-08-11 2021-08-11
PCT/US2022/034747 WO2022271962A1 (en) 2021-06-23 2022-06-23 Formulations of factor viii chimeric proteins and uses thereof

Publications (1)

Publication Number Publication Date
CO2023017358A2 true CO2023017358A2 (es) 2024-01-15

Family

ID=82656587

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0017358A CO2023017358A2 (es) 2021-06-23 2023-12-14 Formulaciones de proteínas quiméricas del factor viii y usos de las mismas

Country Status (12)

Country Link
US (1) US20240287158A1 (es)
EP (1) EP4358938A1 (es)
JP (1) JP2024522855A (es)
KR (1) KR20240024949A (es)
AU (1) AU2022298798A1 (es)
BR (1) BR112023026782A2 (es)
CA (1) CA3220564A1 (es)
CO (1) CO2023017358A2 (es)
IL (1) IL309309A (es)
MX (1) MX2023015238A (es)
TW (1) TW202317178A (es)
WO (1) WO2022271962A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202400657A (zh) * 2022-03-08 2024-01-01 美商百歐維拉提夫治療公司 治療a型血友病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
BRPI0921429B1 (pt) * 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
SG10201913893XA (en) 2012-07-11 2020-03-30 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
CN117106095A (zh) 2014-01-10 2023-11-24 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
BR112020022164A2 (pt) * 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
BR112021025426A2 (pt) * 2019-06-19 2022-06-21 Bioverativ Therapeutics Inc Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
EP4013389A1 (en) * 2019-08-16 2022-06-22 Octapharma AG Stabilizing buffer for factor viii and vwf

Also Published As

Publication number Publication date
TW202317178A (zh) 2023-05-01
BR112023026782A2 (pt) 2024-03-12
IL309309A (en) 2024-02-01
EP4358938A1 (en) 2024-05-01
WO2022271962A1 (en) 2022-12-29
MX2023015238A (es) 2024-03-08
JP2024522855A (ja) 2024-06-21
AU2022298798A1 (en) 2024-02-08
KR20240024949A (ko) 2024-02-26
US20240287158A1 (en) 2024-08-29
CA3220564A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
CO2023017358A2 (es) Formulaciones de proteínas quiméricas del factor viii y usos de las mismas
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
UY37463A (es) Proteínas de unión
HRP20220960T1 (hr) Kimerni proteini faktora viii i njihova upotreba
AR091735A1 (es) Complejo de factor viii con xten y proteina factor de von willebrand (vwf) y usos del mismo
CO2020014566A2 (es) Métodos de tratamiento de la hemofilia a
MD3830120T3 (ro) Noi proteine de fuziune specifice pentru CD137 și PD-L1
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
AR089324A1 (es) Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas
CL2020002718A1 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
CO2023000048A2 (es) Conjugados de citoquina
CL2022000094A1 (es) Anticuerpos anti-cd63, conjugados y usos de estos (divisional de la solicitud no. 202002965)
CL2022003281A1 (es) Inducción de haploides en plantas.
UY37975A (es) Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos
CO2024004211A2 (es) Formulaciones de proteínas quiméricas de factor viii y usos de las mismas
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
AR118853A1 (es) Formulaciones farmacéuticas que contienen proteínas de fusión fc de dominio extracelular de cd80
MX2020003810A (es) Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.
BR112019004337A2 (pt) peptídeo isolado, polipeptídeo isolado, método para modificar um peptídeo, ácido nucleico isolado, construção genética, célula, métodos produção de um agente, de promoção de proliferação celular e de cicatrizar de uma ferida, agente, composição farmacêuticae anticorpo
AR118063A1 (es) Composición para mejorar el cultivo y la implantación de embriones de mamíferos, procedimiento de preparación y uso de la misma
ECSP24035412A (es) Dendrones peptídicos y métodos de uso de los mismos
PL437901A1 (pl) Probówka do wytwarzania fibryny bogatopłytkowej oraz sposób wytwarzania fibryny bogatopłytkowej
BR112023002484A2 (pt) Vacinas anticoronavírus
EA201992692A1 (ru) Нацеленные на msln триспецифические белки и способы применения